JP2987488B2 - Solid dialysis agent and method for producing the same - Google Patents

Solid dialysis agent and method for producing the same

Info

Publication number
JP2987488B2
JP2987488B2 JP7197648A JP19764895A JP2987488B2 JP 2987488 B2 JP2987488 B2 JP 2987488B2 JP 7197648 A JP7197648 A JP 7197648A JP 19764895 A JP19764895 A JP 19764895A JP 2987488 B2 JP2987488 B2 JP 2987488B2
Authority
JP
Japan
Prior art keywords
chloride
dialysis agent
calcium chloride
solid dialysis
double salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP7197648A
Other languages
Japanese (ja)
Other versions
JPH0940562A (en
Inventor
和彦 玉川
秀幸 青山
操 元木
修治 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOMITA SEIYAKU KK
Original Assignee
TOMITA SEIYAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOMITA SEIYAKU KK filed Critical TOMITA SEIYAKU KK
Priority to JP7197648A priority Critical patent/JP2987488B2/en
Priority to KR1019960015192A priority patent/KR100398299B1/en
Priority to TW085105568A priority patent/TW516961B/en
Publication of JPH0940562A publication Critical patent/JPH0940562A/en
Application granted granted Critical
Publication of JP2987488B2 publication Critical patent/JP2987488B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1666Apparatus for preparing dialysates by dissolving solids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、塩化ナトリウム、
塩化カリウム、塩化カルシウム、塩化マグネシウム及び
酢酸ナトリウムからなる電解質組成物及びpH調整剤を
必須成分とし、任意成分としてブドウ糖を含む固形透析
用剤及びその製造方法に関する。
The present invention relates to sodium chloride,
The present invention relates to a solid dialysis agent comprising, as essential components, an electrolyte composition comprising potassium chloride, calcium chloride, magnesium chloride and sodium acetate and a pH adjuster, and glucose as an optional component, and a method for producing the same.

【0002】[0002]

【従来の技術】現在、透析用剤としては、重炭酸透析用
剤が主に用いられているが、これらは多数の電解質成分
を濃厚溶液にしたA剤と重炭酸ナトリウムを粉末あるい
は水溶液にしたB剤の2剤からなっている。このうち、
液剤の形態で使用されている製剤について、ここ数年、
液剤であるが故の問題が多く取り上げられるようになっ
てきた。一般に、この濃厚溶液はポリエチレン容器に包
装されており、A剤は通常10kg程度の重量のものが
販売されている。このような液体の透析剤では重量及び
容積が必然的に大きくなり輸送コスト及び病院での保管
スペースの問題、病院内での運搬性の悪さ等が問題とな
っている。
2. Description of the Related Art At present, as a dialysis agent, a bicarbonate dialysis agent is mainly used. However, these agents are prepared by converting a plurality of electrolyte components into a concentrated solution of agent A and sodium bicarbonate into a powder or an aqueous solution. It consists of two agents, agent B. this house,
In the past few years, about the formulation used in the form of liquid,
Many problems due to the use of liquids have been taken up. Generally, the concentrated solution is packaged in a polyethylene container, and the agent A is usually sold in a weight of about 10 kg. The weight and volume of such a liquid dialysate are inevitably increased, and there are problems of transportation cost, storage space in a hospital, poor transportability in a hospital, and the like.

【0003】さらに、10リットルにもおよぶ使用後の
包装容器の廃棄方法においては、焼却するとしても容積
が大きく、且つ、有害なガスを発生するなどの問題があ
り、包装形態の見直しが要求されている。
[0003] Further, in the method of discarding used packaging containers of up to 10 liters, there is a problem that even if incinerated, the volume is large and harmful gas is generated. ing.

【0004】そこで、このような問題を解決する手段の
一つとして透析用剤の粉剤化が注目されている。
[0004] As one of means for solving such a problem, powdering of a dialysis agent has attracted attention.

【0005】従来より、透析用剤の粉剤化技術としては
乾式造粒法及び湿式造粒法がよく知られているが、両者
とも各電解質組成物の粒度、比重等の相違による成分の
ばらつきを避けるために、各電解質組成物を粉砕して均
一混合したのち、造粒することで成分の均一性を保持し
ている。このような製造法は、粉砕、造粒といった煩雑
で物理的な工程が必要となり、製剤が汚染されやすい状
況にあるといえる。
Conventionally, dry granulation and wet granulation are well-known techniques for pulverizing a dialysis agent, but both of these techniques reduce variations in components due to differences in the particle size and specific gravity of each electrolyte composition. In order to avoid this, each of the electrolyte compositions is pulverized, uniformly mixed, and then granulated to maintain the uniformity of the components. Such a production method requires complicated physical steps such as pulverization and granulation, and it can be said that the preparation is easily contaminated.

【0006】そのうえ、粉砕した電解質組成物を使用し
た製剤は、一般に嵩が高く、流動性に劣るため、安息角
も高値を示す。これらが原因で包装形態を大きくした
り、製剤取り出し時に流動性の悪さの影響で一度に大量
の製剤が投入されるなどの問題がある。一方、溶解時に
は、水を急速に製剤内部に取り込みやすい性状であると
いう利点はあるが、一部では製剤の崩壊速度より吸水に
よる固結化が進み堅固な塊状物を形成させ、溶解速度を
著しく低下させる現象が多々みられる。この他、スプレ
ードライによる粉剤化も知られているが、同様に上記の
ような問題が残されており、透析用剤の粉剤化に向け
て、日々研究が重ねられている。
[0006] In addition, preparations using the pulverized electrolyte composition generally have high bulk and poor fluidity, and thus exhibit a high angle of repose. For these reasons, there is a problem that the packaging form is enlarged, and a large amount of preparation is supplied at once due to poor fluidity at the time of taking out the preparation. On the other hand, at the time of dissolution, there is an advantage that water is rapidly taken into the inside of the preparation, but in some cases, solidification due to water absorption progresses due to the disintegration rate of the preparation to form a solid mass, and the dissolution rate is markedly increased. There are many phenomena that lower it. In addition, powdering by spray drying is also known. However, the above-mentioned problem still remains, and research is being conducted daily to powderize dialysis agents.

【0007】[0007]

【発明が解決しようとする課題】本発明の目的は、重炭
酸透析液を調製するための固形透析用製剤において、新
たな製造方法を提供するとともに、カサ比重、安息角及
び溶解速度が非常に良好であり、透析液を調製する際の
作業性を向上させ、かつ、包装容積を縮小することによ
る輸送コストの低減、病院等での保管スペースの削減、
及び包装容器の廃棄の簡便化が可能な製剤を提供するこ
とにある。
SUMMARY OF THE INVENTION It is an object of the present invention to provide a novel method for preparing a solid dialysis preparation for preparing a bicarbonate dialysate, and to provide a bulk specific gravity, an angle of repose and a dissolution rate that are extremely high. It is good, improves workability when preparing dialysis fluid, and reduces transportation costs by reducing the packaging volume, reducing storage space in hospitals, etc.
Another object of the present invention is to provide a preparation capable of simplifying disposal of a packaging container.

【0008】[0008]

【課題を解決するための手段】本発明は、塩化ナトリウ
ム、塩化カリウム、塩化カルシウム、塩化マグネシウム
及び酢酸ナトリウムの電解質組成物及びpH調整剤を必
須成分とし、任意成分としてのブドウ糖を含む固形透析
用剤において、(1)塩化ナトリウム及び塩化カリウム
からなる群から選ばれる少なくとも1種を主成分として
含む核層;及び(2)酢酸ナトリウムと塩化カルシウム
の反応により生成した複塩、他の電解質組成物及びpH
調整剤及び任意成分としてブドウ糖を含む複塩層;の二
層構造を有する固形透析用剤(以下、第1発明という)
を提供するものである。
DISCLOSURE OF THE INVENTION The present invention relates to a solid dialysis system comprising an electrolyte composition of sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate and a pH adjuster as essential components, and glucose as an optional component. (1) a core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component; and (2) a double salt formed by a reaction between sodium acetate and calcium chloride, and another electrolyte composition And pH
A solid dialysis agent having a two-layer structure of a regulator and a double salt layer containing glucose as an optional component (hereinafter referred to as the first invention).
Is provided.

【0009】また、本発明は、塩化ナトリウム、塩化カ
リウム、塩化カルシウム、塩化マグネシウム及び酢酸ナ
トリウムからなる電解質組成物、pH調整剤及びブドウ
糖を必須成分として含む固形透析用剤において、(1)
塩化ナトリウム及び塩化カリウムからなる群から選ばれ
る少なくとも1種を主成分として含む核層(中心);
(2)酢酸ナトリウムと塩化カルシウムの反応により生
成した複塩、他の電解質組成物及びpH調整剤を含む複
塩層(中間層);および(3)ブドウ糖を含む外層;の
三層構造を有する固形透析用剤(以下、第2発明とい
う)を提供するものである。
Further, the present invention provides a solid dialysis agent comprising an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjuster and glucose as essential components.
A core layer (center) containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component;
It has a three-layer structure of (2) a double salt layer (intermediate layer) containing a double salt produced by the reaction of sodium acetate and calcium chloride, another electrolyte composition and a pH adjuster; and (3) an outer layer containing glucose. The present invention provides a solid dialysis agent (hereinafter, referred to as a second invention).

【0010】更に、本発明は、塩化ナトリウム、塩化カ
リウム、塩化マグネシウム及び酢酸ナトリウムの混合物
に水を加え、内温50〜100℃程度の加温下に塩化カ
ルシウムを加え、かつ、塩化カルシウムを加えたときの
混合物中の水の含量が塩化カルシウムの20〜300重
量%程度である混合造粒工程、整粒、乾燥及びpH調整
剤を加えて混合する工程を含み、塩化ナトリウム及び塩
化カリウムからなる群から選ばれる少なくとも1種を主
成分として含む核層と、酢酸ナトリウムと塩化カルシウ
ムの反応により生成した複塩、他の電解質組成物および
pH調整剤を含む複塩層との二層構造を有するブドウ糖
を必須成分としない固形透析用剤の製造方法(ブドウ糖
を必須成分としない第1発明の製造法)を提供するもの
である。
Further, the present invention relates to a method of adding water to a mixture of sodium chloride, potassium chloride, magnesium chloride and sodium acetate, adding calcium chloride at an internal temperature of about 50 to 100 ° C., and adding calcium chloride. The mixture has a water content of about 20 to 300% by weight of calcium chloride, and comprises a granulation step, a sizing step, a drying step, and a step of adding and mixing a pH adjuster, and comprises sodium chloride and potassium chloride. It has a two-layer structure of a core layer containing at least one member selected from the group as a main component, a double salt formed by a reaction between sodium acetate and calcium chloride, and a double salt layer containing another electrolyte composition and a pH adjuster. An object of the present invention is to provide a method for producing a solid dialysis agent which does not contain glucose as an essential component (the production method of the first invention which does not make glucose an essential component).

【0011】さらにまた、本発明は、塩化ナトリウム、
塩化カリウム、塩化マグネシウム及び酢酸ナトリウム及
びブドウ糖の混合物に水を加え、内温50〜80℃程度
の加温下に塩化カルシウムを加え、かつ、塩化カルシウ
ムを加えたときの混合物中の水の含量が塩化カルシウム
の重量の20〜100重量%程度である混合造粒工程、
及び塩化カルシウム添加後pH調整剤を加え混合する工
程、整粒及び乾燥工程を含み、塩化ナトリウム及び塩化
カリウムからなる群から選ばれる少なくとも1種を主成
分として含む核層と、酢酸ナトリウムと塩化カルシウム
の反応により生成した複塩、他の電解質組成物、ブドウ
糖及びpH調整剤を含む複塩層との二層構造を有するブ
ドウ糖を必須成分とする固形透析用剤の製造方法(ブド
ウ糖を必須成分とする第1発明の製造法)を提供するも
のである。
[0011] Furthermore, the present invention relates to a sodium chloride,
Water is added to a mixture of potassium chloride, magnesium chloride, sodium acetate, and glucose, and calcium chloride is added under heating at an internal temperature of about 50 to 80 ° C., and the content of water in the mixture when calcium chloride is added is A mixing granulation step that is about 20 to 100% by weight of the weight of calcium chloride;
And a step of adding and mixing a pH adjuster after addition of calcium chloride, a sizing step and a drying step, a core layer containing at least one selected from the group consisting of sodium chloride and potassium chloride as a main component, sodium acetate and calcium chloride A method for producing a solid dialysis agent comprising as an essential component glucose having a double-layered structure comprising a double salt formed by the reaction of the double salt, another electrolyte composition, glucose and a double salt layer containing a pH adjuster (glucose is an essential component) (The production method of the first invention).

【0012】さらにまた、本発明は、上記のブドウ糖を
必須成分としない第1発明の製造法により得た造粒物
で、かつ、pH調整剤を添加していない二層構造の固形
透析用剤を内温30〜80℃程度、好ましくは40〜6
0℃程度、さらに好ましくは40〜50℃程度の加温下
にブドウ糖を加え混合し、該固形透析用剤とブドウ糖の
総重量の0.5〜5.0重量%程度の水の存在下に混合
造粒する工程、該造粒物に酢酸を添加し混合する工程及
び乾燥する工程を含む、塩化ナトリウム及び塩化カリウ
ムからなる群から選ばれる少なくとも1種を主成分とし
て含む核層と、酢酸ナトリウムと塩化カルシウムの反応
により生成した複塩、他の電解質組成物及びpH調整剤
を含む複塩層と、ブドウ糖を含む外層との三層構造を有
する固形透析用剤の製造方法(第2発明の製造法)を提
供するものである。
Further, the present invention relates to a two-layered solid dialysis agent which is a granulated product obtained by the production method of the first invention which does not contain glucose as an essential component and which does not contain a pH adjuster. The internal temperature is about 30 to 80 ° C, preferably 40 to 6
Glucose is added and mixed at a temperature of about 0 ° C, more preferably about 40 to 50 ° C, and mixed with the solid dialysis agent and water at about 0.5 to 5.0% by weight of the total weight of glucose. A core layer containing at least one selected from the group consisting of sodium chloride and potassium chloride as a main component, comprising a step of mixing and granulating, a step of adding and mixing acetic acid to the granulated substance, and a step of drying; Of a solid dialysis agent having a three-layer structure of a double salt layer containing a double salt formed by the reaction of calcium chloride with calcium chloride, another electrolyte composition and a pH adjuster, and an outer layer containing glucose (the second invention) Manufacturing method).

【0013】[0013]

【発明の実施の形態】BEST MODE FOR CARRYING OUT THE INVENTION

(I)第1発明及び第2発明の固形透析用剤について 第2発明の固形透析用剤は、ブドウ糖を必須成分としな
い第1発明の固形透析用剤の外側をブドウ糖を含む外層
で被覆したものであり、第1発明のブドウ糖を含む透析
用剤のように、複塩層中に他の電解質組成物とともに共
存させてもよく、好ましくは第2発明のように外層とし
て被覆するのがよい。
(I) Regarding the solid dialysis agent of the first invention and the second invention The solid dialysis agent of the second invention is obtained by coating the outside of the solid dialysis agent of the first invention which does not contain glucose with an outer layer containing glucose. And may coexist with another electrolyte composition in the double salt layer, like the dialysis agent containing glucose of the first invention, and is preferably coated as an outer layer as in the second invention. .

【0014】本発明の固形透析用剤は、炭酸水素ナトリ
ウムと併用することにより重炭酸透析用剤として使用す
ることができる。
The solid dialysis agent of the present invention can be used as a bicarbonate dialysis agent when used in combination with sodium bicarbonate.

【0015】本発明の固形透析用剤は、固体であれば、
粉末状、顆粒状、細粒状などのいずれの状態であっても
よい。また、その形状は、図1に示すように1粒子に前
記核層(1)が1つ含まれた、やや丸みを帯びた立方体
ないしそれに近い形状のものであってもよく、図2に示
すように1粒子に複数の核層(1)が複塩層(2)を介
して結合した形態のいずれであってもよい。なお、第2
発明の場合には、図1の複塩層(2)を取り囲む状態で
ブドウ糖を含む外層(3)が存在してもよく(図3A参
照)、図2の複塩層の外側に外層(3)が形成されたも
のであってもよい(図3B)。
If the solid dialysis agent of the present invention is a solid,
It may be in any state such as a powder, a granule, and a fine granule. Further, as shown in FIG. 1, the shape may be a slightly rounded cube in which one core layer (1) is included in one particle or a shape close thereto, as shown in FIG. As described above, any of the forms in which a plurality of core layers (1) are bonded to one particle via a double salt layer (2) may be used. The second
In the case of the invention, an outer layer (3) containing glucose may be present in a state surrounding the double salt layer (2) in FIG. 1 (see FIG. 3A), and the outer layer (3) may be provided outside the double salt layer in FIG. ) May be formed (FIG. 3B).

【0016】本発明の固形透析用剤は、X線回折におい
て、酢酸ナトリウムと塩化カルシウムの反応により生成
した複塩に由来する2θ=約6.8〜7.0°(X線:
Cuλ(Kα1)=1.5405オングストローム)に
特定のピークを示す。前記複塩を形成することにより、
核層に含まれていない各電解質組成物においては、成分
の均一性を保持するために何らかの工程、例えば、粉砕
や粒度調整という工程を必要とすることなく、組成的に
均一に核層を被覆する効果がある。
In the solid dialysis agent of the present invention, in X-ray diffraction, 2θ = about 6.8 to 7.0 ° derived from a double salt formed by the reaction between sodium acetate and calcium chloride (X-ray:
A specific peak is shown at Cuλ (Kα1) = 1.5405 Å. By forming the double salt,
In each of the electrolyte compositions not included in the core layer, the core layer is uniformly coated compositionally without any process for maintaining the uniformity of the components, for example, a process of pulverization or particle size adjustment. Has the effect of doing

【0017】固形透析用剤の内部に存在する塩化ナトリ
ウム及び塩化カリウムからなる群から選ばれる少なくと
も1種を主成分として含む核層の粒子径は、150〜2
000μm程度、好ましくは250〜1000μm程
度、より好ましくは250〜800μm程度である。
The particle size of the core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride present in the solid dialysis agent as a main component is 150 to 2
It is about 000 μm, preferably about 250 to 1000 μm, and more preferably about 250 to 800 μm.

【0018】電解質組成物の各成分の好ましい比率を、
電解質組成物全体を100重量%として以下に示す。
A preferable ratio of each component of the electrolyte composition is as follows:
The total amount of the electrolyte composition is shown below as 100% by weight.

【0019】 塩化ナトリウム=75.9〜94.6重量%程度; 塩化カリウム=1.1〜4.1重量%程度; 塩化カルシウム=1.1〜4.0重量%程度; 塩化マグネシウム=0.8〜2.8重量%程度; 酢酸ナトリウム=2.4〜13.5重量%程度。Sodium chloride = about 75.9 to 94.6% by weight; potassium chloride = about 1.1 to 4.1% by weight; calcium chloride = about 1.1 to 4.0% by weight; magnesium chloride = 0. Sodium acetate = about 2.4 to 13.5% by weight.

【0020】また、電解質組成物100重量部に対する
pH調整剤及びブドウ糖の比率を以下に示す。
The ratio of the pH adjuster and glucose to 100 parts by weight of the electrolyte composition is shown below.

【0021】pH調整剤=0.8〜3.6重量部程度; ブドウ糖=0〜29.6重量部程度。PH adjuster = about 0.8 to 3.6 parts by weight; glucose = about 0 to 29.6 parts by weight.

【0022】pH調整剤としては、薬理学的に許容され
る液体酸及び固体酸であれば特に制限されず、例えば酢
酸、塩酸などの液体酸及びクエン酸、リンゴ酸などの固
体酸が挙げられる。
The pH adjuster is not particularly limited as long as it is a pharmacologically acceptable liquid acid and solid acid, and examples thereof include liquid acids such as acetic acid and hydrochloric acid and solid acids such as citric acid and malic acid. .

【0023】本発明の固形透析用剤は、カサ比重が0.
77〜2.0g/ml程度、好ましくは1.0〜1.5
g/ml程度である。また、安息角は35°程度以下、
好ましくは30°程度以下である。
The solid dialysis agent of the present invention has a bulk specific gravity of 0.1.
About 77 to 2.0 g / ml, preferably 1.0 to 1.5
g / ml. Also, the angle of repose is about 35 ° or less,
Preferably it is about 30 ° or less.

【0024】重炭酸透析用剤として使用する際の本発明
の固形透析用剤と炭酸水素ナトリウムの使用比率は、固
形透析用剤100重量部に対して炭酸水素ナトリウムが
23.0〜39.0重量部程度である。
The ratio of the solid dialysis agent of the present invention to sodium bicarbonate when used as a bicarbonate dialysis agent is such that sodium bicarbonate is 23.0 to 39.0 based on 100 parts by weight of the solid dialysis agent. It is about parts by weight.

【0025】さらに、本発明固形透析用剤をケイ素酸化
物を含み且つ透湿度(40℃、90%RH)2.0g/
cm2・24hr以下の包材(以下、シリカ蒸着フィル
ムと称する)に包装することで安定性に優れた製剤を得
ることを可能とした。
Further, the solid dialysis agent of the present invention contains silicon oxide and has a water vapor transmission rate (40 ° C., 90% RH) of 2.0 g /
By packaging in a packaging material (hereinafter, referred to as a silica-deposited film) having a size of cm 2 · 24 hr or less, it became possible to obtain a preparation having excellent stability.

【0026】(II)第1発明及び第2発明の固形透析用
剤の製造法について 第1発明の固形透析用剤は、塩化ナトリウム、塩化カリ
ウム、塩化マグネシウム及び酢酸ナトリウムの混合物に
水を加え、内温50〜100℃程度の加温下に塩化カル
シウムを加え混合造粒し、造粒物を常法により整粒、乾
燥し、その後pH調整剤を加えて混合する工程を経るこ
とにより製造される。
(II) Method for Producing Solid Dialysis Agent of the First and Second Inventions The solid dialysis agent of the first invention is obtained by adding water to a mixture of sodium chloride, potassium chloride, magnesium chloride and sodium acetate, Calcium chloride is added under heating at an internal temperature of about 50 to 100 ° C., and the mixture is granulated. The granulated product is sized and dried by a conventional method, and then a pH adjusting agent is added and mixed. You.

【0027】なお、水は、塩化カルシウムを加える時点
までに加えておくのが好ましく、塩化カルシウム水溶液
として加えてもよい。
The water is preferably added before the time of adding calcium chloride, and may be added as an aqueous solution of calcium chloride.

【0028】水の添加量は、各電解質組成物の結晶水、
付着水を含めて、塩化カルシウムの重量の20〜300
重量%程度、好ましくは30〜200重量%程度、より
好ましくは40〜100重量%程度である。
The amount of water to be added depends on the water of crystallization of each electrolyte composition,
20-300 of the weight of calcium chloride, including attached water
%, Preferably about 30 to 200% by weight, more preferably about 40 to 100% by weight.

【0029】一方、ブドウ糖を含む場合の第1発明の固
形透析用剤は、塩化ナトリウム、塩化カリウム、塩化マ
グネシウム及び酢酸ナトリウム及びブドウ糖の混合物に
水を加え、内温50〜80℃程度の加温下に塩化カルシ
ウムを加え混合造粒し、塩化カルシウム添加後pH調整
剤を加えて混合をしたのち、造粒物を常法により整粒、
乾燥することにより製造される。
On the other hand, the solid dialysis agent of the first invention containing glucose is prepared by adding water to a mixture of sodium chloride, potassium chloride, magnesium chloride, sodium acetate and glucose, and heating the mixture to an internal temperature of about 50 to 80 ° C. Calcium chloride is added and granulated underneath, and after adding calcium chloride, a pH adjuster is added and mixed, and the granulated material is sized by a conventional method.
It is manufactured by drying.

【0030】この場合の水の添加量は、各電解質組成物
の結晶水、付着水を含めて、塩化カルシウムの重量の2
0〜100重量%程度である。
In this case, the amount of water to be added is 2% of the weight of calcium chloride, including water of crystallization and adhesion of each electrolyte composition.
It is about 0 to 100% by weight.

【0031】水を加えた後は、内温50〜100℃程度
(ブドウ糖を含む場合は50〜80℃程度)の温度下で
塩化カルシウムを添加、混合することにより酢酸ナトリ
ウムと塩化カルシウムの反応を生じ、前記複塩層を形成
し、この造粒物を整粒、乾燥するだけで目的とする二層
構造を有する固形透析用剤が得られる。
After the addition of water, calcium chloride is added and mixed at a temperature of about 50 to 100 ° C. (about 50 to 80 ° C. when glucose is contained) to thereby react sodium acetate and calcium chloride. Then, the double salt layer is formed, and the granulated product is sized and dried to obtain a solid dialysis agent having a desired two-layer structure.

【0032】第1発明で得られたブドウ糖とpH調整剤
を含まない二層構造の固形透析用剤を内温30〜80℃
程度、好ましくは40〜60℃程度、さらに好ましくは
40〜50℃程度の加温下にブドウ糖を加えて混合し、
該固形透析用剤とブドウ糖の総重量の0.5〜5.0重
量%程度の水の存在下に混合造粒する工程、該造粒物に
酢酸を添加し、混合した後、乾燥するとさらにブドウ糖
を含む外層を有する第2発明の三層構造の固形透析用剤
が得られる。水の量は、固形透析用剤とブドウ糖の総重
量の0.5〜5.0重量%程度、好ましくは1.0〜
3.0重量%程度である。
The double-layered solid dialysis agent containing no glucose and a pH adjuster obtained in the first invention is treated at an internal temperature of 30 to 80 ° C.
About, preferably about 40 to 60 ° C., more preferably about 40 to 50 ° C., and adding and mixing glucose under heating.
A step of mixing and granulating in the presence of about 0.5 to 5.0% by weight of water of the total weight of the solid dialysis agent and glucose, adding acetic acid to the granulated substance, mixing, and then drying. The solid dialysis agent having a three-layer structure of the second invention having an outer layer containing glucose is obtained. The amount of water is about 0.5 to 5.0% by weight, preferably 1.0 to 5.0% by weight of the total weight of the solid dialysis agent and glucose.
It is about 3.0% by weight.

【0033】各成分の配合比率は上記の通りである。The mixing ratio of each component is as described above.

【0034】[0034]

【発明の効果】本第1及び第2発明の固形透析用剤は、
従来の乾式ないし湿式造粒、スプレードライなどの方法
により粉剤化された製剤に比べ、溶解速度において有意
に優れており、溶解過程で固結が生じるおそれはなく、
造粒物の表面である各層から順に溶解する製剤構造を有
している。
The solid dialysis agents of the first and second inventions are
Compared to powdered preparations by conventional dry or wet granulation, spray-drying, etc., the dissolution rate is significantly superior, there is no risk of caking during the dissolution process,
It has a formulation structure that dissolves in order from each layer that is the surface of the granulated material.

【0035】また、カサ比重は極めて高く、安息角も良
好である。
Further, the bulk specific gravity is extremely high and the angle of repose is good.

【0036】このような特性を有する本発明品は、透析
液を調製する際の作業性を著しく向上させるものであ
り、且つ、包装容積を著しく縮小することが可能なた
め、輸送コストの低減、病院での保管スペースの削減が
可能である。
The product of the present invention having such characteristics significantly improves the workability in preparing a dialysis solution, and can significantly reduce the packaging volume, thereby reducing transportation costs, The storage space at the hospital can be reduced.

【0037】さらに、焼却可能な包材を使用しているた
め廃棄の簡便化、及び、透湿性の極めて少ない包材であ
ることからブドウ糖の安定性に優れた製剤を確立でき
た。特に第2発明の透析用剤は、ブドウ糖の安定性が極
めて良好である。
Furthermore, since a packaging material that can be incinerated is used, simplification of disposal can be achieved, and a packaging material having excellent glucose stability can be established because the packaging material has extremely low moisture permeability. In particular, the dialysis agent of the second invention has extremely good glucose stability.

【0038】[0038]

【実施例】以下、本発明を実施例に基づきより詳細に説
明する。
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below in more detail with reference to embodiments.

【0039】実施例1 以下の表1に示す各原料を使用した。Example 1 Each raw material shown in Table 1 below was used.

【0040】[0040]

【表1】 塩化ナトリウム 250.20kg 塩化カリウム 6.15kg 塩化カルシウム 9.07kg 塩化マグネシウム 4.27kg 酢酸ナトリウム 20.34kg 酢酸 4.96kg 先ず、平均粒径約350μmである塩化ナトリウムを使
用し、塩化カリウム、塩化マグネシウム、酢酸ナトリウ
ムと純水4.7リットルを二重缶式攪拌混合機(蒸気加
熱)に入れ、攪拌しながら加熱し、内容物温度を70℃
とした。この混合物に塩化カルシウムを添加し、混合し
た。
[Table 1] Sodium chloride 250.20 kg Potassium chloride 6.15 kg Calcium chloride 9.07 kg Magnesium chloride 4.27 kg Sodium acetate 20.34 kg Acetic acid 4.96 kg First, use sodium chloride having an average particle size of about 350 μm, and use potassium chloride, magnesium chloride, and sodium acetate. And 4.7 liters of pure water are put into a double can type stirring mixer (steam heating) and heated while stirring, and the temperature of the contents is reduced to 70 ° C.
And Calcium chloride was added to the mixture and mixed.

【0041】塩化カルシウム添加の15分後に内容物は
やや白色を増し、更に内容物温度70℃を維持した状態
で加熱混合を続けると、内容物に特異的な粘りが生じ、
内容物の粒子同士が付着し始めた。そして、内容物を取
り出し、整粒したのち、乾燥し、酢酸を加えて混合、製
品を回収した。
After 15 minutes from the addition of calcium chloride, the content becomes slightly whiter, and when the content is heated and mixed while maintaining the content temperature at 70 ° C., the content has specific viscosity.
The particles of the contents began to adhere to each other. Then, the contents were taken out, sized, dried, acetic acid was added and mixed, and the product was collected.

【0042】得られた製剤の平均粒径は約500μmで
ある。
The average particle size of the obtained preparation is about 500 μm.

【0043】実施例1により得た製剤の構造について、
以下に詳細を示す。
Regarding the structure of the preparation obtained according to Example 1,
Details are shown below.

【0044】先ず、図4に顕微鏡像を示し、造粒物全体
の形状について説明する。
First, FIG. 4 shows a microscope image, and the shape of the whole granulated product will be described.

【0045】本製剤は、各々1個の核層及び複塩層を有
する1粒子またはこれらが複数個結合した製剤であるこ
とが図4から明らかである。一方、1粒子の断面を電子
顕微鏡像(図5)で観察すると、核層と外層(複塩層)
との二重構造がはっきりと示されている。
It is apparent from FIG. 4 that the present preparation is a single particle having one core layer and one double salt layer, or a preparation in which a plurality of these particles are combined. On the other hand, when the cross section of one particle is observed by an electron microscope image (FIG. 5), the nucleus layer and the outer layer (double salt layer)
And the double structure is clearly shown.

【0046】また、本製剤は、図6に示すX線回折(X
線:CuKα1)に示すように、各使用原料から起因す
るピークを除くと、2θ=7.0゜付近に特異的なピー
クを持つ。これが、酢酸ナトリウムと塩化カルシウムの
水熱反応により生じた複塩である。
Further, the preparation was prepared by the X-ray diffraction (X-ray diffraction) shown in FIG.
As shown in the line: CuKα 1 ), there is a specific peak around 2θ = 7.0 °, excluding the peaks originating from each raw material used. This is a double salt produced by a hydrothermal reaction between sodium acetate and calcium chloride.

【0047】そして、二層構造を持つ1粒子の成分につ
いて、図7に示す1粒子の断面線上を粒子核側から外層
(複塩層)へと、電子線マイクロアナライズ(EPMA)で分
析すると、粒子核層では、Na,Clのみの検出、外層
(複塩層)ではCa,Mg,Kの検出とCl,Naの検
出量の低下がみられた(図8)。これらの結果から、核
層が塩化ナトリウムであり、外層がCa,Mg,Kを含
む層、すなわち酢酸ナトリウムと塩化カルシウムの水熱
反応により生じた複塩層であり、この複塩層内に他の電
解質組成物を含んでいることがわかる。
The components of one particle having a two-layer structure are analyzed by electron beam microanalysis (EPMA) from the particle nucleus side to the outer layer (double salt layer) on the sectional line of one particle shown in FIG. In the particle nucleus layer, only Na and Cl were detected, and in the outer layer (double salt layer), Ca, Mg, and K were detected, and the detected amounts of Cl and Na were decreased (FIG. 8). From these results, the core layer is sodium chloride, and the outer layer is a layer containing Ca, Mg, and K, that is, a double salt layer formed by a hydrothermal reaction between sodium acetate and calcium chloride. It can be seen that the electrolyte composition of the present invention is contained.

【0048】従って、本実施例の製剤は、塩化ナトリウ
ムからなる核層と酢酸ナトリウムと塩化カルシウムの反
応により生成した他の電解質組成物及びpH調整剤とし
ての酢酸を含む複塩層(X線回折において、2θ=7.
0゜付近(X線:CuKα1)にピークを持つ)との二
層構造を持つ1粒子、また、生成した複塩が結合剤とな
り、これら粒子を複数個結合したものである。
Therefore, the preparation of this example is characterized in that a core layer composed of sodium chloride, another electrolyte composition formed by the reaction of sodium acetate and calcium chloride, and a double salt layer containing acetic acid as a pH adjuster (X-ray diffraction In 2θ = 7.
One particle having a two-layer structure of around 0 ° (having a peak at X-ray: CuKα 1 ), and the double salt formed as a binder, and a plurality of these particles are combined.

【0049】また、得られた製品からランダムに5個の
検体を取り、それぞれの検体について検体7.161g
と第2製剤である炭酸水素ナトリウム2.52gを水に
溶かして正確に1000mlとした液につき、Na+
+,Ca2+、Mg2+、Cl-、CH3COO-の各電解質
イオン濃度をダイオネックス社製のイオンクロマトグラ
フにて測定した。結果を以下の表2に示す。
Also, five samples were randomly taken from the obtained product, and 7.161 g of each sample was obtained.
When the second formulation is a sodium bicarbonate 2.52g per liquid was accurately 1000ml dissolved in water, Na +,
The electrolyte ion concentrations of K + , Ca 2+ , Mg 2+ , Cl , and CH 3 COO were measured using an ion chromatograph manufactured by Dionex. The results are shown in Table 2 below.

【0050】[0050]

【表2】 [Table 2]

【0051】以上の結果から、本製剤は組成的に非常に
均一な製剤であることがわかる。
From the above results, it can be seen that the present preparation is a very homogeneous composition.

【0052】比較例1 酢酸を除く以外は表1と同じ各電解質原料を50μm程
度に粉砕し、混合した原料を乾式造粒機にて造粒し、整
粒した。得られた造粒物に酢酸を添加して混合し、透析
用製剤を得た。得られた製剤の平均粒径は約800μm
であった。
Comparative Example 1 The same electrolyte raw materials as in Table 1 except that acetic acid was excluded were ground to about 50 μm, and the mixed raw materials were granulated by a dry granulator and sized. Acetic acid was added to the obtained granules and mixed to obtain a preparation for dialysis. The average particle size of the obtained formulation is about 800 μm
Met.

【0053】比較例2 酢酸を除く以外は表1と同じ各電解質原料を50μm程
度に粉砕し、混合した原料に、5重量%の水を添加して
混合した。この混合物を押し出し造粒機にて造粒、整粒
した後、温度70℃で箱形乾燥機にて3時間乾燥させ
た。得られた造粒物に酢酸を添加して混合し、透析用製
剤を得た。得られた製剤の平均粒径は約700μmであ
った。
Comparative Example 2 The same electrolyte raw materials as in Table 1 except that acetic acid was removed were ground to about 50 μm, and 5% by weight of water was added to the mixed raw materials and mixed. This mixture was granulated by an extrusion granulator and sized, and then dried at a temperature of 70 ° C. by a box dryer for 3 hours. Acetic acid was added to the obtained granules and mixed to obtain a preparation for dialysis. The average particle size of the obtained preparation was about 700 μm.

【0054】比較例3 酢酸を除く以外は表1と同じ各電解質原料を攪拌槽内で
攪拌下温水(40℃)に溶解して濃度約25%の濃厚水
溶液とした。この濃厚水溶液を連続噴霧乾燥機(入口温
度360〜380℃、出口温度160〜180℃)中で
オリフィス孔径1.3m/mのノズルより送液ポンプ圧
10kg/cm2下に加圧噴霧乾燥させた。得られた造
粒物に酢酸を添加して混合し、透析用製剤を得た。得ら
れた製剤の平均粒径は約200μmであった。
Comparative Example 3 The same electrolyte raw materials as in Table 1 except for acetic acid were dissolved in warm water (40 ° C.) with stirring in a stirring tank to obtain a concentrated aqueous solution having a concentration of about 25%. This concentrated aqueous solution is spray-dried in a continuous spray dryer (inlet temperature: 360 to 380 ° C., outlet temperature: 160 to 180 ° C.) from a nozzle having an orifice hole diameter of 1.3 m / m under a liquid sending pump pressure of 10 kg / cm 2. Was. Acetic acid was added to the obtained granules and mixed to obtain a preparation for dialysis. The average particle size of the obtained preparation was about 200 μm.

【0055】図9に比較例1、図10に比較例2及び図
11に比較例3のX線回折結果を示す(X線:Cu K
α1)。
FIG. 9 shows the X-ray diffraction results of Comparative Example 1, FIG. 10 shows Comparative Example 2 and FIG. 11 shows the X-ray diffraction results of Comparative Example 3 (X-ray: Cu K
α 1 ).

【0056】図6(実施例1)と図9〜11の比較から
明らかなように、実施例1のX線回折のチャートにのみ
2θ=7.0°付近に、酢酸ナトリウムと塩化カルシウ
ムの水熱反応により形成された他の電解質組成物および
pH調整剤を含む複塩のピークが検出されており、他の
X線回折の結果とは明らかに異なることがわかる。
As is clear from the comparison between FIG. 6 (Example 1) and FIGS. 9 to 11, only the X-ray diffraction chart of Example 1 shows that the water content of sodium acetate and calcium chloride was around 2θ = 7.0 °. The peaks of the double salt containing the other electrolyte composition and the pH adjuster formed by the thermal reaction are detected, and it can be seen that the peaks are clearly different from other X-ray diffraction results.

【0057】次に、製剤の特性について以下に詳細を示
す。
Next, the characteristics of the preparation will be described in detail below.

【0058】[0058]

【表3】 [Table 3]

【0059】溶解速度の測定は、1000mlのビーカ
ーに水500ml(20℃)を入れ、攪拌機(攪拌速度
300rpm)にて攪拌しながら実施例1及び比較例1
〜3の各製剤を150g投入し、完全に溶解するまでの
時間を測定した。
The dissolution rate was measured by placing 500 ml of water (20 ° C.) in a 1000 ml beaker and stirring with a stirrer (stirring speed 300 rpm) in Example 1 and Comparative Example 1.
150 g of each of the preparations Nos. To 3 was charged, and the time required for complete dissolution was measured.

【0060】表3に示すように、本発明の製剤は、カサ
比重が他に比べて高く、粒子密度の高い製剤であり、そ
の上安息角も25°と低く、流動性の良いものであるこ
とがわかる。
As shown in Table 3, the preparation of the present invention has a higher bulk density and a higher particle density than the others, and also has a low angle of repose of 25 ° and good fluidity. You can see that.

【0061】従って、製剤に占める容積が少ないため、
輸送コストの低減、病院等での保管スペースの削減が図
れる。
Therefore, since the volume occupying the preparation is small,
It is possible to reduce transportation costs and storage space in hospitals and the like.

【0062】また、溶解速度も速く、流動性の良い点も
含め、透析液を調製するにあたり非常に取り扱いやすい
製剤であり、今後、透析用剤の粉末化に向け重要な製剤
であるといえる。
In addition, it is a preparation that is very easy to handle in preparing a dialysate, including its high dissolution rate and good flowability, and can be said to be an important preparation for powdering dialysis agents in the future.

【0063】実施例2 以下の表4に示す各原料を使用した。Example 2 The raw materials shown in Table 4 below were used.

【0064】[0064]

【表4】 塩化ナトリウム 250.20kg 塩化カリウム 6.15kg 塩化カルシウム 9.07kg 塩化マグネシウム 4.27kg 酢酸ナトリウム 20.34kg 酢酸 4.96kg ブドウ糖 41.33kg 先ず、平均粒径約350μmの塩化ナトリウムを使用
し、塩化カリウム、塩化マグネシウム、酢酸ナトリウ
ム、ブドウ糖と純水4.7リットルを二重缶式攪拌混合
機(蒸気加熱)に入れ、攪拌しながら加熱し、内容物温
度を60℃とした。この混合物に塩化カルシウムを添加
し、混合した。
[Table 4] Sodium chloride 250.20 kg Potassium chloride 6.15 kg Calcium chloride 9.07 kg Magnesium chloride 4.27 kg Sodium acetate 20.34 kg Acetic acid 4.96 kg Glucose 41.33 kg First, sodium chloride having an average particle size of about 350 μm is used, and potassium chloride, magnesium chloride, Sodium acetate, glucose and 4.7 liters of pure water were put into a double can type stirring mixer (steam heating) and heated while stirring to bring the content temperature to 60 ° C. Calcium chloride was added to the mixture and mixed.

【0065】塩化カルシウム添加の15分後に内容物は
やや白色を増し、更に内容物温度60℃を維持した状態
で加熱混合を続けると、内容物に特異的な粘りが生じ、
内容物の粒子同士が付着し始めた。そして、酢酸を添加
し混合すると、特異的な粘りはやや消失した。その後、
該造粒物を取り出し、整粒したのち、乾燥して製品を回
収した。
After 15 minutes from the addition of calcium chloride, the content becomes slightly whiter, and when the content is further heated and mixed while maintaining the content temperature at 60 ° C., specific stickiness is produced in the content,
The particles of the contents began to adhere to each other. Then, when acetic acid was added and mixed, the specific stickiness slightly disappeared. afterwards,
The granulated product was taken out, sized, and dried to recover the product.

【0066】得られた製剤の平均粒径は約600μmで
ある。
The average particle size of the obtained preparation is about 600 μm.

【0067】また、図12に示すX線回折(X線:Cu
Kα1)に示すように、実施例1と同様に、2θ=7.
0゜付近に特異的なピークを持ち、酢酸ナトリウムと塩
化カルシウムの水熱反応により生じた複塩の形成が確認
できる。
The X-ray diffraction (X-ray: Cu
As shown in Kα 1 ), 2θ = 7.
It has a specific peak near 0 °, and the formation of a double salt generated by the hydrothermal reaction between sodium acetate and calcium chloride can be confirmed.

【0068】実施例3 上記の表4に示す各原料を使用した。Example 3 The raw materials shown in Table 4 above were used.

【0069】先ず、平均粒径約350μmの塩化ナトリ
ウムを使用し、塩化カリウム、塩化マグネシウム、酢酸
ナトリウムと純水4.7リットルを二重缶式攪拌混合機
(蒸気加熱)に入れ、攪拌しながら加熱し、内容物温度
を70℃とした。この混合物に塩化カルシウムを添加
し、混合した。
First, using sodium chloride having an average particle size of about 350 μm, potassium chloride, magnesium chloride, sodium acetate and 4.7 liters of pure water are put into a double-can stirring mixer (steam heating), and the mixture is stirred. Heat to bring the contents temperature to 70 ° C. Calcium chloride was added to the mixture and mixed.

【0070】塩化カルシウム添加の15分後に内容物は
やや白色を増し、更に内容物温度70℃を維持した状態
で加熱混合を続けると、内容物に特異的な粘りが生じ、
内容物の粒子同士が付着し始めた。そして、内容物を取
り出し、整粒し、乾燥した。
Fifteen minutes after the addition of calcium chloride, the content becomes slightly whiter, and if the content is further heated and mixed while maintaining the content temperature at 70 ° C., specific stickiness is produced in the content,
The particles of the contents began to adhere to each other. Then, the contents were taken out, sized, and dried.

【0071】この造粒物を攪拌式混合機に入れ、水を造
粒物に対して1%添加して混合し、内容物を50℃に加
温した。ここにブドウ糖を加えて混合すると10分後に
特異的な粘りが生じ、更に5分間混合した後、酢酸を加
えて混合した。10分後、この特異的な粘りが消失し、
さらさらした造粒物に変化した。この造粒物を水分が
0.5%以下になるまで乾燥し、製品を回収した。
The granules were placed in a stirring mixer, water was added to the granules at 1% and mixed, and the contents were heated to 50 ° C. When glucose was added thereto and mixed, specific stickiness was generated after 10 minutes, and after further mixing for 5 minutes, acetic acid was added and mixed. After 10 minutes, this specific stickiness disappears,
It turned into a fluffy granulate. The granulated product was dried until the water content became 0.5% or less, and the product was recovered.

【0072】得られた製剤の平均粒径は約600μm
で、水分は0.35%であった。
The average particle size of the obtained preparation is about 600 μm
And the water content was 0.35%.

【0073】実施例3で得た製剤の電子顕微鏡像を図1
3に示す。
An electron microscope image of the preparation obtained in Example 3 is shown in FIG.
3 is shown.

【0074】塩化ナトリウムの粒子からなる核層(内
層)、酢酸ナトリウムと塩化カルシウムの水熱反応によ
り形成された他の電解質組成物及び酢酸を含んだ複塩層
(中間層)及びブドウ糖層(外層)の三層構造を有して
いることが明確にわかる。
A core layer (inner layer) composed of sodium chloride particles, a double salt layer (intermediate layer) containing acetic acid and another electrolyte composition formed by a hydrothermal reaction between sodium acetate and calcium chloride, and a glucose layer (outer layer) ) Clearly has a three-layer structure.

【0075】次に、実施例3のX線回折(X線:CuK
α1)の結果を図14に示す。使用原料に起因するX線
回折のピーク以外に、2θ=7.0゜付近にピークが検
出され、これが酢酸ナトリウムと塩化カルシウムの水熱
反応により形成された複塩であることがわかる。
Next, the X-ray diffraction of Example 3 (X-ray: CuK
α 1 ) is shown in FIG. In addition to the X-ray diffraction peak due to the raw materials used, a peak was detected near 2θ = 7.0 °, indicating that this was a double salt formed by the hydrothermal reaction of sodium acetate and calcium chloride.

【0076】また、得られた製品からランダムに5個の
検体を取り、それぞれの検体について、検体8.161
gと第2剤である炭酸水素ナトリウム2.52gを水に
溶かして正確に1000mlとした液につき、Na+
+,Ca2+、Mg2+、Cl-、CH3COO-の各電解質
イオン濃度をダイオネックス社製のイオンクロマトグラ
フ、ブドウ糖濃度を液体クロマトグラフにて測定した。
結果を以下の表5に示す。
Also, five samples were randomly taken from the obtained product, and for each sample, sample 8.161 was obtained.
g + 2.52 g of sodium bicarbonate as a second agent in water to make exactly 1000 ml, Na + ,
The electrolyte ion concentration of each of K + , Ca 2+ , Mg 2+ , Cl , and CH 3 COO was measured by an ion chromatograph manufactured by Dionex, and the glucose concentration was measured by a liquid chromatograph.
The results are shown in Table 5 below.

【0077】[0077]

【表5】 [Table 5]

【0078】以上の結果から、本製剤が組成的に非常に
均一な製剤であることがわかる。
From the above results, it can be seen that the present preparation is a very homogeneous composition.

【0079】比較例4 表4に示す各原料を攪拌式混合機に全量投入し、20分
間混合後、製品とした比較例4のX線回折(X線:Cu
Kα1)の結果を図15に示すが、2θ=7.0゜付近
に実施例3のようなピークは確認されなかった。
Comparative Example 4 All the raw materials shown in Table 4 were put into a stirring mixer, mixed for 20 minutes, and then subjected to X-ray diffraction (X-ray: Cu
The results of Kα 1 ) are shown in FIG. 15, but no peak was observed near 2θ = 7.0 ° as in Example 3.

【0080】一方、実施例3及び比較例4の製剤をそれ
ぞれシリカ蒸着フィルム袋に充填し、ヒートシールによ
り密封した。
On the other hand, the preparations of Example 3 and Comparative Example 4 were respectively filled in silica-deposited film bags and sealed by heat sealing.

【0081】40℃(RH=75%)の条件下で安定性
試験を行い、検体20.4gを水を加えて溶かし、正確
に100mlとした液について、日本薬局方第12改正
のブドウ糖注射液中の5−ヒドロキシメチルフルフラー
ル類の測定法にて吸光度を測定した。結果を表6に示
す。
A stability test was conducted at 40 ° C. (RH = 75%), and 20.4 g of a sample was dissolved by adding water to make exactly 100 ml. The absorbance was measured by a method for measuring 5-hydroxymethylfurfural in the solution. Table 6 shows the results.

【0082】[0082]

【表6】 [Table 6]

【0083】表6の結果より、本発明製剤は、6ヶ月を
経た後でも、ブドウ糖分解物が少ないことがわかる。
From the results shown in Table 6, it can be seen that the preparation of the present invention has little glucose decomposed product even after 6 months.

【図面の簡単な説明】[Brief description of the drawings]

【図1】第1発明の製剤の構造を示す模式図である。FIG. 1 is a schematic view showing the structure of the preparation of the first invention.

【図2】第1発明の製剤の構造を示す模式図である。FIG. 2 is a schematic view showing the structure of the preparation of the first invention.

【図3】第1発明の製剤の構造を示す模式図である。FIG. 3 is a schematic view showing the structure of the preparation of the first invention.

【図4】実施例1で得られた固形透析用剤の光学顕微鏡
像を示す。
FIG. 4 shows an optical microscope image of the solid dialysis agent obtained in Example 1.

【図5】実施例1で得られた固形透析用剤の電子顕微鏡
像を示す。
FIG. 5 shows an electron microscopic image of the solid dialysis agent obtained in Example 1.

【図6】実施例1で得られた固形透析用剤のX線回折の
結果を示す。
FIG. 6 shows the result of X-ray diffraction of the solid dialysis agent obtained in Example 1.

【図7】実施例1で得られた固形透析用剤の電子線マイ
クロアナライズの分析結果を示す。
7 shows the results of electron microanalysis of the solid dialysis agent obtained in Example 1. FIG.

【図8】実施例1で得られた固形透析用剤の電子線マイ
クロアナライズの分析結果を示す。
FIG. 8 shows the results of electron microanalysis of the solid dialysis agent obtained in Example 1.

【図9】比較例1で得られた固形透析用剤のX線回折の
結果を示す。
9 shows the result of X-ray diffraction of the solid dialysis agent obtained in Comparative Example 1. FIG.

【図10】比較例2で得られた固形透析用剤のX線回折
の結果を示す。
10 shows the result of X-ray diffraction of the solid dialysis agent obtained in Comparative Example 2. FIG.

【図11】比較例3で得られた固形透析用剤のX線回折
の結果を示す。
FIG. 11 shows the result of X-ray diffraction of the solid dialysis agent obtained in Comparative Example 3.

【図12】実施例2で得られた固形透析用剤のX線回折
の結果を示す。
FIG. 12 shows the results of X-ray diffraction of the solid dialysis agent obtained in Example 2.

【図13】実施例3で得られた固形透析用剤の電子顕微
鏡像を示す。
FIG. 13 shows an electron microscopic image of the solid dialysis agent obtained in Example 3.

【図14】実施例3で得られた固形透析用剤のX線回折
の結果を示す。
FIG. 14 shows the results of X-ray diffraction of the solid dialysis agent obtained in Example 3.

【図15】比較例4で得られた固形透析用剤のX線回折
の結果を示す。
FIG. 15 shows the result of X-ray diffraction of the solid dialysis agent obtained in Comparative Example 4.

【符号の説明】[Explanation of symbols]

1 核層 2 複塩層 3 外層 1 core layer 2 double salt layer 3 outer layer

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 33:06 31:19) (A61K 33/14 33:06 31:19 31:70) (56)参考文献 特開 平2−311418(JP,A) 特開 平6−178802(JP,A) 特開 平6−237991(JP,A) 特開 平8−169836(JP,A) 特開 平7−59846(JP,A) 特開 平4−257522(JP,A) (58)調査した分野(Int.Cl.6,DB名) A61K 31/00 - 33/44 ──────────────────────────────────────────────────続 き Continuation of the front page (51) Int.Cl. 6 Identification code FI A61K 33:06 31:19) (A61K 33/14 33:06 31:19 31:70) (56) References JP-A-6-178802 (JP, A) JP-A-6-279991 (JP, A) JP-A-8-169836 (JP, A) JP-A-7-59846 (JP, A) JP-A-4-257522 (JP, A) (58) Fields investigated (Int. Cl. 6 , DB name) A61K 31/00-33/44

Claims (15)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 塩化ナトリウム、塩化カリウム、塩化カ
ルシウム、塩化マグネシウム及び酢酸ナトリウムからな
る電解質組成物とpH調整剤を含む固形透析用剤におい
て、塩化ナトリウム及び塩化カリウムからなる群から選
ばれる少なくとも1種を主成分として含む核層と、酢酸
ナトリウムと塩化カルシウムの反応により生成した複
塩、他の電解質組成物およびpH調整剤を含む複塩層と
の二層構造を有する固形透析用剤。
1. A solid dialysis agent comprising an electrolyte composition comprising sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate and a pH adjuster, at least one selected from the group consisting of sodium chloride and potassium chloride. A solid dialysis agent having a two-layer structure of a core layer containing as a main component, a double salt formed by the reaction of sodium acetate and calcium chloride, and a double salt layer containing another electrolyte composition and a pH adjuster.
【請求項2】 前記複塩層にブドウ糖を更に含む請求項
1に記載の固形透析用剤。
2. The solid dialysis agent according to claim 1, wherein the double salt layer further contains glucose.
【請求項3】 前記核層の平均粒径が150〜2000
μmである請求項1又は2に記載の固形透析用剤。
3. The core layer has an average particle size of 150 to 2,000.
3. The solid dialysis agent according to claim 1, which has a particle size of μm.
【請求項4】 前記pH調整剤が酢酸である請求項1〜
3のいずれかに記載の固形透析用剤。
4. The method according to claim 1, wherein the pH adjuster is acetic acid.
3. The solid dialysis agent according to any one of 3.
【請求項5】 酢酸ナトリウムと塩化カルシウムの反応
により生成した複塩が、X線回折において、2θ=6
8°〜7.0°(X線:Cu λ(Kα1)=1.54
05オングストローム)に特定のピークを有する請求項
1〜4のいずれかに記載の固形透析用剤。
5. A double salt formed by a reaction between sodium acetate and calcium chloride is obtained by X-ray diffraction at 2θ = 6 .
8 ° to 7.0 ° (X-ray: Cu λ (Kα1) = 1.54
The solid dialysis agent according to any one of claims 1 to 4, which has a specific peak at 0.05 angstrom).
【請求項6】 請求項1〜5のいずれかに記載の固形透
析用剤と炭酸水素ナトリウムの2剤からなる重炭酸透析
用剤。
6. A bicarbonate dialysis agent comprising the solid dialysis agent according to claim 1 and sodium bicarbonate.
【請求項7】 塩化ナトリウム、塩化カリウム、塩化カ
ルシウム、塩化マグネシウム及び酢酸ナトリウムからな
る電解質組成物とpH調整剤およびブドウ糖を含む固形
透析用剤において、塩化ナトリウム及び塩化カリウムか
らなる群から選ばれる少なくとも1種を主成分として含
む核層と、酢酸ナトリウムと塩化カルシウムの反応によ
り生成した複塩、他の電解質組成物およびpH調整剤を
含む複塩層と、ブドウ糖を含む外層との三層構造を有す
る固形透析用剤。
7. A solid dialysis agent containing sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, a pH adjuster and glucose, and at least one selected from the group consisting of sodium chloride and potassium chloride. A three-layer structure consisting of a core layer containing one type as a main component, a double salt formed by the reaction of sodium acetate and calcium chloride, a double salt layer containing another electrolyte composition and a pH adjuster, and an outer layer containing glucose. Solid dialysis agent.
【請求項8】 前記核層の平均粒径が150〜2000
μmである請求項7に記載の固形透析用剤。
8. The core layer has an average particle size of 150 to 2,000.
The solid dialysis agent according to claim 7, which has a particle size of µm.
【請求項9】 前記pH調整剤が酢酸である請求項7又
は8に記載の固形透析用剤。
9. The solid dialysis agent according to claim 7, wherein the pH adjuster is acetic acid.
【請求項10】 酢酸ナトリウムと塩化カルシウムの反
応により生成した複塩が、X線回折において、2θ
.8°〜7.0°(X線:Cu λ(Kα1)=1.
5405オングストローム)に特定のピークを有する請
求項7〜9のいずれかに記載の固形透析用剤。
10. A double salt formed by a reaction between sodium acetate and calcium chloride is determined by X-ray diffraction as 2θ =
6 . 8 ° to 7.0 ° (X-ray: Cu λ (Kα1) = 1.
The solid dialysis agent according to any one of claims 7 to 9, which has a specific peak at 5405 angstroms).
【請求項11】 請求項7〜10のいずれかに記載の固
形透析用剤と炭酸水素ナトリウムの2剤からなる重炭酸
透析用剤。
11. A bicarbonate dialysis agent comprising the solid dialysis agent according to claim 7 and sodium bicarbonate.
【請求項12】 塩化ナトリウム、塩化カリウム、塩化
マグネシウム及び酢酸ナトリウムの混合物に水を加え、
内温50〜100℃の加温下に塩化カルシウムを加え、
かつ、塩化カルシウムを加えたときの混合物中の水の含
量が塩化カルシウムの重量の20〜300重量%である
混合造粒工程、整粒、乾燥及びpH調整剤を加えて混合
する各工程を含むことを特徴とする、塩化ナトリウム及
び塩化カリウムからなる群から選ばれる少なくとも1種
を主成分として含む核層と、酢酸ナトリウムと塩化カル
シウムの反応により生成した複塩、他の電解質組成物お
よびpH調整剤を含む複塩層との二層構造を有する固形
透析用剤の製造方法。
12. Water is added to a mixture of sodium chloride, potassium chloride, magnesium chloride and sodium acetate,
Calcium chloride is added under heating at an internal temperature of 50-100 ° C ,
And a mixing granulation step in which the content of water in the mixture when calcium chloride is added is 20 to 300 % by weight of the weight of calcium chloride , a granulating step, drying, and a step of adding and mixing a pH adjuster. A core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component, a double salt produced by a reaction between sodium acetate and calcium chloride, another electrolyte composition and pH adjustment A method for producing a solid dialysis agent having a two-layer structure with a double salt layer containing the agent.
【請求項13】 塩化ナトリウム、塩化カリウム、塩化
マグネシウム及び酢酸ナトリウム及びブドウ糖の混合物
に水を加え、内温50〜80℃の加温下に塩化カルシウ
ムを加え、かつ、塩化カルシウムを加えたときの混合物
中の水の含量が塩化カルシウムの重量の20〜100重
%である混合造粒工程、及び塩化カルシウム添加後p
H調整剤を加え混合する工程、整粒及び乾燥工程を含む
ことを特徴とする、塩化ナトリウム及び塩化カリウムか
らなる群から選ばれる少なくとも1種を主成分として含
む核層と、酢酸ナトリウムと塩化カルシウムの反応によ
り生成した複塩、他の電解質組成物、ブドウ糖及びpH
調整剤を含む複塩層との二層構造を有する固形透析用剤
の製造方法。
13. A method of adding water to a mixture of sodium chloride, potassium chloride, magnesium chloride, sodium acetate and glucose, adding calcium chloride at an internal temperature of 50 to 80 ° C. , and adding calcium chloride. A mixing granulation step in which the content of water in the mixture is 20 to 100 % by weight of the weight of calcium chloride, and p after addition of calcium chloride
A core layer containing at least one member selected from the group consisting of sodium chloride and potassium chloride as a main component, comprising a step of adding and mixing an H adjuster, a step of sizing and drying; and a step of mixing sodium acetate and calcium chloride. Double salt, other electrolyte composition, glucose and pH produced by the reaction of
A method for producing a solid dialysis agent having a two-layer structure with a double salt layer containing a regulator.
【請求項14】 塩化ナトリウム、塩化カリウム、塩化
マグネシウム及び酢酸ナトリウムの混合物に水を加え、
内温50〜100℃の加温下に塩化カルシウムを加え、
かつ、塩化カルシウムを加えたときの混合物中の水の含
量が塩化カルシウムの重量の20〜300重量%である
混合造粒工程、整粒及び乾燥する各工程により得た二層
構造の固形透析用剤を、内温30〜80℃の加温下にブ
ドウ糖を加え混合し、該固形透析用剤とブドウ糖の総重
量の0.5〜5.0重量%の水の存在下で混合造粒する
工程、該造粒物にpH調整剤を添加し混合する工程及び
乾燥工程を含むことを特徴とする、塩化ナトリウム及び
塩化カリウムからなる群から選ばれる少なくとも1種を
主成分として含む核層と、酢酸ナトリウムと塩化カルシ
ウムの反応により生成した複塩、他の電解質組成物及び
pH調整剤を含む複塩層と、ブドウ糖を含む外層との三
層構造を有する固形透析用剤の製造方法。
14. Sodium chloride, potassium chloride, chloride
Adding water to the mixture of magnesium and sodium acetate,
Calcium chloride is added under heating at an internal temperature of 50-100 ° C,
And the water content of the mixture when calcium chloride is added.
The amount is 20-300% by weight of the weight of calcium chloride
Two layers obtained by mixing granulation process, sizing and drying processes
Glucose is added to the solid dialysis agent having the above structure while heating at an internal temperature of 30 to 80 ° C., and the mixture is mixed in the presence of 0.5 to 5.0% by weight of water of the total weight of the solid dialysis agent and glucose. A step of mixing and granulating the mixture, a step of adding and mixing a pH adjuster to the granulated substance, and a drying step, wherein at least one selected from the group consisting of sodium chloride and potassium chloride is used as a main component. Nuclear layer containing, double salt generated by the reaction of sodium acetate and calcium chloride, a double salt layer containing another electrolyte composition and a pH adjuster, and a solid dialysis agent having a three-layer structure of an outer layer containing glucose Production method.
【請求項15】 請求項1、2または7に記載の固形透
析用剤を、ケイ素酸化物を含み且つ透湿度(40℃90
%RH)2.0g/cm2・24hr以下の包材に包装
してなる包装固形透析用剤。
15. The solid dialysis agent according to claim 1, comprising silicon oxide and having a water vapor transmission rate (40 ° C. 90
% RH) A packaged solid dialysis agent packaged in a packaging material of 2.0 g / cm 2 · 24 hr or less.
JP7197648A 1995-08-02 1995-08-02 Solid dialysis agent and method for producing the same Expired - Fee Related JP2987488B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP7197648A JP2987488B2 (en) 1995-08-02 1995-08-02 Solid dialysis agent and method for producing the same
KR1019960015192A KR100398299B1 (en) 1995-08-02 1996-05-09 Solid dialysis solvent and method for manufacturing the same
TW085105568A TW516961B (en) 1995-08-02 1996-05-10 Preparation for dialysis and method of preparing solid preparation for dialysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7197648A JP2987488B2 (en) 1995-08-02 1995-08-02 Solid dialysis agent and method for producing the same

Publications (2)

Publication Number Publication Date
JPH0940562A JPH0940562A (en) 1997-02-10
JP2987488B2 true JP2987488B2 (en) 1999-12-06

Family

ID=16377997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7197648A Expired - Fee Related JP2987488B2 (en) 1995-08-02 1995-08-02 Solid dialysis agent and method for producing the same

Country Status (3)

Country Link
JP (1) JP2987488B2 (en)
KR (1) KR100398299B1 (en)
TW (1) TW516961B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192960A1 (en) * 2000-09-27 2002-04-03 Nipro Corporation Solid preparation for dialysis and process for producing the same
JP2008023146A (en) * 2006-07-24 2008-02-07 Manac Inc Solid formulation for dialysis and method for producing the same

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987488B2 (en) * 1995-08-02 1999-12-06 富田製薬株式会社 Solid dialysis agent and method for producing the same
WO2001060428A1 (en) * 2000-02-16 2001-08-23 Teijin Limited Dialyzing fluid preparing device and powdery dialyzing fluid preparing chemical
JP4292695B2 (en) * 2000-07-31 2009-07-08 ソニー株式会社 Disc receiving plate and disc recording and / or reproducing apparatus
DE10162959B4 (en) * 2001-12-20 2017-10-12 Fresenius Medical Care Deutschland Gmbh Container containing at least two solids and its use
WO2004067014A1 (en) * 2003-01-31 2004-08-12 Manac Inc. Solid preparation for dialysis and process for producing the same
JP4561978B2 (en) * 2004-10-29 2010-10-13 味の素株式会社 Solid dialysis agent and method for producing the same
JP4626718B2 (en) * 2010-01-08 2011-02-09 味の素株式会社 Solid dialysis agent
JP2010088936A (en) * 2010-01-15 2010-04-22 Ajinomoto Co Inc Solid agent a for dialysis which has improved solubility
JP5376480B1 (en) * 2012-10-10 2013-12-25 富田製薬株式会社 A dialysis agent containing acetic acid and acetate, and two-agent dialysis agent using the same
JP6562336B2 (en) * 2014-12-11 2019-08-21 富田製薬株式会社 Method for producing granulated material used for dialysis agent A
CN107811988A (en) * 2017-11-27 2018-03-20 北京市四维医药科技研究所 A kind of composite electrolyte cored shape piece
CN107823165A (en) * 2017-11-27 2018-03-23 北京市四维医药科技研究所 A kind of flat cylindricality piece of composite electrolyte
CN107753506A (en) * 2017-11-27 2018-03-06 北京市四维医药科技研究所 Stable composite electrolyte solid pharmaceutical preparation
CN107753450A (en) * 2017-11-27 2018-03-06 北京市四维医药科技研究所 A kind of composite electrolyte three-layer tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2749375B2 (en) * 1989-05-26 1998-05-13 テルモ 株式会社 Preparation for hemodialysis and method for producing the same
JPH04257522A (en) * 1991-02-07 1992-09-11 Nikkiso Co Ltd Dialyzing agent for sodium bicarbonate
JP2769592B2 (en) * 1992-12-14 1998-06-25 富田製薬株式会社 Method for producing artificial kidney perfusion agent for bicarbonate dialysis and artificial kidney perfusion agent
JP3187580B2 (en) * 1992-12-25 2001-07-11 川澄化学工業株式会社 Multilayer solid dialysis agent
JP3398184B2 (en) * 1993-03-30 2003-04-21 味の素ファルマ株式会社 Dialysis agent
JP3589489B2 (en) * 1994-09-12 2004-11-17 サイテック株式会社 Drug used for dispensing dialysate and dissolving dispensing method
JP2987488B2 (en) * 1995-08-02 1999-12-06 富田製薬株式会社 Solid dialysis agent and method for producing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192960A1 (en) * 2000-09-27 2002-04-03 Nipro Corporation Solid preparation for dialysis and process for producing the same
JP2008023146A (en) * 2006-07-24 2008-02-07 Manac Inc Solid formulation for dialysis and method for producing the same

Also Published As

Publication number Publication date
TW516961B (en) 2003-01-11
JPH0940562A (en) 1997-02-10
KR970009819A (en) 1997-03-27
KR100398299B1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
JP2987488B2 (en) Solid dialysis agent and method for producing the same
JP2769592B2 (en) Method for producing artificial kidney perfusion agent for bicarbonate dialysis and artificial kidney perfusion agent
CA1167378A (en) Dry dialysate products
RU2403033C2 (en) Solubilised ibuprofen
JP4760381B2 (en) Solid preparation for dialysis and production method thereof
JPH05501421A (en) Pharmaceutical compositions that are rapidly suspended in water
TW200911287A (en) Solid preparation for dialysis
CA2734847A1 (en) Novel excipient for mannitol tableting
CA2664420A1 (en) Effervescent ibuprofen formulation with high dissolution rate and process for its preparation
PL176005B1 (en) Effervescent granular substance and method of obtaining same
JPH06205959A (en) Spherical granule, its production and medicine using the same
EP1192960B1 (en) Solid preparation for dialysis and process for producing the same
JP3530235B2 (en) Hemodialysis agent
JP4603977B2 (en) Dialysis solid preparation and method for producing the same
JP2005206572A (en) One tablet type solid agent for bicarbonate dialysis and method for producing the same
TWI324989B (en) Powderous trace element, method and device for its production
JP4945108B2 (en) Isosorbide preparation
JP2809971B2 (en) Hemodialysis preparation
JP3415291B2 (en) Bicarbonate dialysis agent
AU661139B2 (en) Preparation of granular alkali metal borate compositions
JP2986256B2 (en) Granules for hemodialysis
JP3635653B2 (en) Method for producing solid dialysis agent
JPH10259133A (en) Particulate agent for dialysis and its production
EP0143576A1 (en) An antacid composition and a process for the preparation thereof
WO2004066977A1 (en) Solid agent for dialysis and process for producing the same

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101008

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101008

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111008

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111008

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121008

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121008

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131008

Year of fee payment: 14

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees